Open-label, Non-randomized Phase 2 Study With Safety Run-in Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Lymphoma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Bimiralisib (Primary)
- Indications Lymphoid leukaemia; Lymphoma
- Focus Therapeutic Use
- Sponsors PIQUR Therapeutics
- 12 Dec 2020 This trial has been Discontinued in Germany, according to European Clinical Trials Database record.
- 20 Mar 2019 Status changed from active, no longer recruiting to completed.
- 06 Nov 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.